TGFB1 and neoplasm: Thus, this unique nature of TGF-β makes it a good candidate for a variety of pre-clinical and clinical studies to assess tumor-suppressing or tumor-promoting responses to TGF-β signaling-associated therapies in different types of cancers [28].